Company intelligence / Profile preview
Manifold Bio
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
Manifold Bio has developed a proprietary high-throughput in vivo drug design platform using protein barcoding ("mCodes") that enables simultaneous testing of hundreds of therapeutic candidates within living systems. The company’s approach allows rapid optimization and selection of targeted biologic drugs with improved efficacy and safety profiles. Internal programs are focused on oncology and neuromedicine; no clinical results have been published yet as the pipeline remains preclinical.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Protein therapeutics (including antibodies, cell engagers, ADCs)Engineered biologics (shuttles for tissue targeting)Conditionally activated biologicsHalf-life extension technologiesSubcutaneous administration platforms
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Manifold Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Manifold Bio.